Pharmacia
Drugs banned in developed world sold in India: Parliamentary Panel
Connections
Quotes
We are excited about the opportunity to build a commercial stage business in Oncology together with CPRIT. Craig’s success at ILEX Oncology together with over 20 years of operating and M&A experience at Pharmacia Pharmacia Latest from The Business Journals Follow this company and Enzon is a great addition to the Texas life science landscape and the Spindletop Capital teamMore quotes »
Around the web
-
The Drug Shock of the Year - FDA Approved, But Beware
By Dr. Mercola In a dramatic move that shows that the U.S. FDA is softening its stand on bio-pharmed treatments, the agency has approved the country's first genetically modified plant intended for the treatment of a human disease. An Israeli firm grew hu from Mercola Read more »
-
How can Kalamazoo nurture more science-based companies? Southwest Michigan Innovation Center CEO Robert DeWit will offer insights
Courtesy of WMUDeWit is former Upjohn/Pharmacia/Pfizer executive who became leader of the Innovation Center in 2008 KALAMAZOO, MI – Cultivating the growth of the 11-year-old Southwest Michigan Innovation Center will be the topic when Robert DeWit, presid from MLive.com Read more »
-
Bayer CropScience, Pharmacia sued by feds and Mass.
Bayer Cropscience AG Rice farmer Prasert Tempiyapon (left) and Bayer CropScience employee Amena Prommin inspect the rice quality on a field approx. 200 km south of Bangkok. ... Read the full story at Business Journal from Albequerque Express Read more »
-
Bayer CropScience, Pharmacia sued by feds and state
This was printed from Boston Business Journal The suits, filed in U.S. District Court against Bayer and Pharmacia, states: "This is a civil claim for natural resource damages...for damages for injury to, destruction of, or loss of natural resources at th from Boston Business Journal Read more »
-
Pfizer says on lookout for mid-size drug deals
(Reuters) - Pfizer Inc, which last week agreed to sell its baby formula business for almost $12 billion, is on the hunt for companies with promising new treatments for diabetes, cancer and neurological conditions, and willing to spend $4 billion or more from Reuters Read more »
